RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
Oct 18, 2016 12:02 pm UTC| Business
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once grantedRedHill’s robust RHB-104 patent portfolio...
RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
Oct 18, 2016 12:02 pm UTC| Business
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once grantedRedHill’s robust RHB-104 patent portfolio...
As Cross-Border Payments Grow, Flywire Thrives
Oct 18, 2016 12:02 pm UTC| Business
BOSTON, Oct. 18, 2016 -- Flywire,a leading provider of cross-border payment solutions, continued its expansion in both the education and healthcare segments in the last six months. In the most recent academic year,...
As Cross-Border Payments Grow, Flywire Thrives
Oct 18, 2016 12:02 pm UTC| Business
BOSTON, Oct. 18, 2016 -- Flywire,a leading provider of cross-border payment solutions, continued its expansion in both the education and healthcare segments in the last six months. In the most recent academic year,...
Catalyst Biosciences Announces Agreement to Sell NNR Asset
Oct 18, 2016 12:02 pm UTC| Business
-- Divestment of Additional Neuronal Nicotinic Receptor Asset to Provide Catalyst with $750,000 Up Front Payment -- -- Catalyst Remains Focused on Improved Factor VIIa and IX Programs to Provide Subcutaneous...
Catalyst Biosciences Announces Agreement to Sell NNR Asset
Oct 18, 2016 12:02 pm UTC| Business
-- Divestment of Additional Neuronal Nicotinic Receptor Asset to Provide Catalyst with $750,000 Up Front Payment -- -- Catalyst Remains Focused on Improved Factor VIIa and IX Programs to Provide Subcutaneous...
Oct 18, 2016 12:02 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been...